#Canada #Quebec #NYSE American #Devonian Health #Fibroinflammatory

Devonian Health Group to Start Trading on NYSE American

On August 18, 2026, Devonian Health Group Inc. announced its plans to commence trading on the NYSE American as they approach the completion of an underwritten public offering. The company, listed under TSXV: GSD and OTCQB: DVHGF, anticipates to launch its common shares and warrants on the NYSE American with trading commencing as early as August 21, 2026, depending on market conditions and the final authorization from the exchange.

Devonian Health, headquartered in Quebec, Canada, has made significant strides in the pharmaceutical sector, specializing in the development of innovative treatment options for auto-immune fibroinflammatory diseases. Their pipeline includes therapies tailored for conditions such as atopic dermatitis, radiodermatitis, and ulcerative colitis.

The decision to move to the NYSE American reflects the company's growth strategy and commitment to enhancing its visibility and accessibility to the U.S. investor market. Upon listing, the company will also change its trading symbol on the TSX Venture Exchange from GSD to DHGR, which they have already reserved. This strategic shift represents a significant milestone in Devonian’s journey, demonstrating their robust development in developing prescription drugs for unmet medical needs.

Founded in 2015, Devonian boasts a state-of-the-art extraction facility and is focused on providing novel therapeutic solutions that address significant medical gaps in the treatment of fibroinflammatory diseases. The company aims to leverage the NYSE American platform to engage with a broader investor base and secure the necessary capital to further its clinical and commercial aspirations.

As Devonian looks ahead, they are committed to rigorous scientific research that underpins their drug development processes. Their approach is centered on understanding the complexities of autoimmune conditions and advancing treatment modalities that not only improve patient quality of life but also address chronic health challenges.

In the coming weeks, investors and stakeholders will be closely observing Devonian Health Group's listing on the NYSE American. With an eye on the market trends, this transition could provide new momentum as Devonian prepares for future clinical trials and product launches. Devonian's entry into the United States trading landscape stands as a testament to its enduring commitment to innovation in healthcare.

During this transitional period, prospective investors are advised to conduct thorough research and consider both the potential and the challenges associated with investments in clinical-stage companies. The biotechnology sector is notoriously volatile, with developments relying heavily on clinical trial outcomes and regulatory approvals.

As Devonian Health Group Inc. embarks on this new chapter, it emphasizes its mission: to develop effective and accessible treatments for autoimmune diseases that can profoundly impact patients’ lives. With an unwavering focus on research and development, Devonian is poised to make significant contributions to the healthcare field.